Buy Survodutide 10mg
GLP-1/glucagon dual agonist for obesity and NASH with superior fat liver targeting
Cheap Survodutide 10mg — Survodutide (BI 456906) is a Phase III GLP-1/glucagon receptor dual agonist from Boehringer Ingelheim with particular efficacy against non-alcoholic steatohepatitis (NASH) and obesity.
- GLP-1/glucagon dual agonism for obesity and NASH simultaneously
- 14.9% body weight loss in Phase II at optimal doses
- Strongest liver fat reduction of any dual agonist in development
- Phase III NASH trial — potential first NASH approval
- Reduces liver steatosis, inflammation, and fibrosis
COA verified · US domestic shipping
Survodutide: The Phase III GLP-1/Glucagon Dual Agonist Targeting Obesity and NASH Simultaneously
NASH Disease Modification
Survodutide is in active Phase III trials as a potential first approved NASH treatment — targeting liver fat, inflammation, and fibrosis simultaneously through glucagon receptor hepatic activation.
Hepatic Glucagon Action
Glucagon receptor activation drives hepatic fatty acid oxidation and reduces de novo lipogenesis — directly targeting the liver fat accumulation at the core of NASH pathology.
14.9% Bodyweight Loss
Phase II obesity data showing 14.9% weight reduction at 46 weeks — competitive with the best established GLP-1 agonists and without the cardiovascular outcome data limitations.
Obesity-NASH Continuum
A single compound addressing both obesity and its most dangerous metabolic complication — survodutide is the only agent in late-stage development designed to treat this disease continuum simultaneously.
The Science Behind Survodutide 10mg
▸Next-Generation GLP-1/Glucagon Dual Agonism
Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase III trials for obesity and NASH. Its glucagon receptor component is particularly potent for hepatic fat reduction — making Survodutide the dual agonist with the strongest evidence for treating both obesity and the associated liver disease (NASH) that is increasingly prevalent in obese populations.
▸NASH Targeting: The Glucagon Advantage
Glucagon receptor activation in hepatocytes directly stimulates hepatic fatty acid oxidation and reduces de novo lipogenesis — the two key drivers of non-alcoholic fatty liver disease. Phase II NASH trials with Survodutide showed marked improvements in liver steatosis, inflammation, and fibrosis scores, positioning it as a potential disease-modifying treatment for NASH — a condition with no approved pharmacotherapy.
▸Phase III Pipeline and Clinical Data
Phase II obesity trials showed 14.9% body weight loss over 46 weeks at optimal doses — competitive with semaglutide and other approved GLP-1 agonists. The Phase III NASH trial is a landmark study with potential to establish Survodutide as the first approved treatment for this condition, which affects over 1.5% of the global population and has no current pharmacological standard of care.
Complete Survodutide 10mg Benefits
- GLP-1/glucagon dual agonism for obesity and NASH simultaneously
- 14.9% body weight loss in Phase II at optimal doses
- Strongest liver fat reduction of any dual agonist in development
- Phase III NASH trial — potential first NASH approval
- Reduces liver steatosis, inflammation, and fibrosis
- Once-weekly dosing for sustained weight and liver fat control
- Addresses the obesity-NASH continuum with a single agent
Survodutide 10mg Dosing Protocol
Reconstitution: Add 2–3mL bacteriostatic water.
Dosing:
• Phase II protocol: 1.2–4.8mg subcutaneous weekly (dose escalation)
• Start: 0.3mg weekly, escalate monthly to target
• Maximum studied: 4.8mg weekly
• Once-weekly subcutaneous injection
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
Survodutide 10mg
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Stack Survodutide 10mg With
HealingNAD+ 100mg
Injectable NAD+ for cellular energy, DNA repair, and anti-aging restoration
Verified NAD+ 100mg — Injectable NAD+ 100mg — the coenzyme central to cellular energy metabolism, sirtuin activation, DNA repair, and mitochondrial biogenesis for comprehensive anti-aging support.
Weight Loss5-Amino-1MQ 50mg
NNMT inhibitor for fat cell reduction, NAD+ elevation, and metabolic enhancement
Buy 5-Amino-1MQ 50mg — 5-Amino-1MQ is a selective NNMT inhibitor that reduces fat cell size, elevates intracellular NAD+, and enhances metabolic rate — the mechanistically novel small molecule for body composition.
Weight LossMazdutide 6mg
GLP-1/glucagon dual agonist for superior weight loss and metabolic control
Trusted Mazdutide 6mg — Mazdutide is a once-weekly GLP-1/glucagon receptor dual agonist in Phase III trials that produces superior weight loss versus GLP-1 monotherapy by adding thermogenic glucagon activation.